Abstract: The present disclosure relates to methods, compositions, and devices for treatments related to mammary tissue in subjects, including reducing the incidence of mastitis. In particular, the disclosure can relate to creating a physical barrier on a teat surface, in a teat canal, or in a teat cistern for prophylactic treatment of mammary disorders.

Abstract: The nanoparticles of the present invention consist of a molecular aggregate containing an amphipathic block polymer that has a hydrophilic block and a hydrophobic block. It is preferable that the amphipathic block polymer be biodegradable. The nanoparticles of the present invention are obtained by granulating into particles an amphipathic block polymer in the presence of an amino acid whose isoelectric point is 7 or less. In one embodiment, the granulation is done by bringing a solution containing an amphipathic block polymer or the dried product thereof into contact with an aqueous liquid. Granulation can be done in the presence of an amino acid by including an amino acid whose isoelectric point is 7 or less in either a solution that contains an amphipathic block polymer or in an aqueous liquid, or in both.

Abstract: An ophthalmic composition is provided that includes rebamipide and a method for preparing the same. The ophthalmic composition of maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range that does not injure the cornea and conjunctiva of a patient suffering from dry eye and has improved stability so as not to be re-dispersed.

Abstract: The present invention describes an oral pharmaceutical composition comprising cannabinoid(s), an oily liquid solvent and a co-solvent, as well as a process for preparing and the same for the treatment of neurological disorders, especially refractory epilepsy. The analytical methods used to ensure identity, quality and purity of Active Pharmaceutical Ingredient and formulation produced were validated and have defined specifications.

Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.

Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.

Abstract: [Problem to be solved] To provide a drug delivery system capable of delivering a drug into a cell expressing a VEGF receptor. [Solution] Provided is a VEGF-binding peptide-drug complex in which a drug is bound to a C-terminal amino acid and/or an N-terminal amino acid of a VEGF-binding peptide and is incorporated into a VEGF receptor-expressing cell by endocytosis of a VEGF receptor, the VEGF-binding peptide having a helix-loop-helix structure including an A block that includes a peptide forming an ?-helix structure and is positioned on an N-terminal side, a C block that includes a peptide forming an ?-helix structure and is positioned on a C-terminal side, and a B block that includes a peptide linking the A block and the C block by a covalent bond.

Abstract: A glycopeptide composition including a plurality of glycopeptides and a therapeutic agent or diagnostic compound is provided. Each of the glycopeptide includes a polysaccharide moiety connected to a peptide moiety, and the polysaccharide moiety is covalently bounded to the peptide moiety via a fixed connection point, wherein the fixed connection point is the same in each of the glycopeptide, and the therapeutic agent or diagnostic is conjugated to each of the glycopeptide.

Abstract: The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.

Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.

Abstract: The present invention provides compounds for use in treating and/or preventing influenza. The compound comprises a first and second domain in which the first domain comprises at least one anchoring group which binds to the surface of influenza viruses and the second domain comprises at least one anionic group. The first and second domains are covalently linked. Also provided are pharmaceutically acceptable salts, solvates, prodrugs or stereoisomer of the compounds.

Abstract: The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.

Abstract: The present invention features methods of directly targeting specific cell surface receptors on the M2 macrophage for antibody or nanoparticle directed therapy.

Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.

Abstract: A method for strengthening the immune response of a weakened immune system, wherein the method includes providing a doses of tissue resonance suppression therapy to a patient and injecting an autologous polyvalent biological vaccine to the patient, wherein the autologous polyvalent biological vaccine was produced from the patient venous blood, a system for performing tissue resonance suppression therapy, a system and a process for the production of the autologous polyvalent biological vaccine for treating cancer, and an autologous polyvalent biological vaccine for personalized and precision medicinal, for treatment of individual cancerous patients, wherein producing a new dose of autologous polyvalent biological vaccine is done from a patient venous blood that was taken after time interval from the time in which a previous venous blood was taken, wherein the vaccine is adapted for treating the individual cancerous patients at a specific stage of his disease, in accordance with embodiments of the present inven

Abstract: The present disclosure provides various linker units and molecular constructs, each of which has a targeting element and an effector element linked therewith. Methods for treating various diseases using such linker units and molecular constructs are also disclosed.

Abstract: The present disclosure relates to an antimicrobial peptide conjugated with nanoparticles, in particular the antimicrobial peptide LL37-conjugated gold nanoparticles for use in medicine or cosmetic, for human or animals, namely in the treatment of wound healing or in the treatment of ischemic or vascular diseases, comprising a gold nanoparticle and a plurality of LL-37 peptides, wherein the plurality of LL-37 peptides is bound to the gold nanoparticle surface.

Abstract: The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances.

Abstract: Processes for precipitating polymers from a polymer-containing solution are disclosed.

Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

Abstract: The invention relates to a nucleic acid molecule for use in a method of treatment of cancer. The nucleic acid molecule comprises a sequence selected from SEQ ID NO 001 to SEQ ID NO 038. The nucleic acid molecules provided are not provided for the treatment of laryngeal cancer.

Abstract: The present invention provides a composition which comprises the following Thyroid Stimulating Hormone Recept or (TSHR) peptides: (i) all or part of the amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1), or a part thereof, or a sequence having at least 60% sequence identity to SEQ ID NO:1; and (ii) all or part of the amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2), or a part thereof, or a sequence having at least 60% sequence identity to SEQ ID NO:2. The present invention also relates to the use of such a composition for the prevention or suppression of activating autoantibody formation in Graves' disease.

Abstract: The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selectively express genes in motor neurons in vitro and in vivo. It is based, at least in part, on the discovery that the nucleic acid of SEQ ID NO: 1 functioned as a motor neuron-specific promoter and was successful in expressing transgenes in motor neuron cells in vivo. The present disclosure also relates to compositions that can increase the activity or expression level of miR-218 and to compositions that can decrease the expression of miR-218 target nucleic acids.

Abstract: The described invention provides a method for reducing progression of lung fibrosis after a lung injury comprising administering a therapeutic amount of a therapeutic agent, wherein the therapeutic amount is effective: (a) to modulate expression of a T-box transcription factor in a population of cells in lung; and (b) to reduce proliferation of the population of cells in lung expressing the T-box transcription factor. According to some embodiments the T-box transcription factor is Tbx4.

Abstract: A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.

Abstract: Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.

Abstract: A composition includes a plurality of gold nanoparticles each having at least one surface. The gold nanoparticles have an average length of at least about 90 nm and an average width of at least about 25 nm.

Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.

Abstract: The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.

Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.

Abstract: The invention is a novel method of sterilizing bone and soft tissues intended for human transplantation. In one embodiment the process includes steps of subjecting transplants to high hydrostatic pressures of aqueous fluid to which chlorhexidine gluconate or similar sterilizing chemicals have been added.

Abstract: Methods and apparatus to reduce biological carryover using induction heating are disclosed herein. An example method includes washing an aspiration and dispense device. The example method includes generating an alternating electromagnetic field and introducing the aspiration and dispense device into the alternating electromagnetic field. The example method includes inductively heating the aspiration and dispense device with the alternating electromagnetic field. In the example method, the washing is to occur in concert with the heating.

Abstract: Ultraviolet radiation is directed within an area. Items located within the area and/or one or more conditions of the area are monitored over a period of time. Based on the monitoring, ultraviolet radiation sources are controlled by adjusting a direction, an intensity, a pattern, and/or a spectral power of the ultraviolet radiation generated by the ultraviolet radiation source. Adjustments to the ultraviolet radiation source(s) can correspond to one of a plurality of selectable operating configurations including a storage life preservation operating configuration, a disinfection operating configuration, and an ethylene decomposition operating configuration.

Abstract: Ultraviolet radiation is directed within an area at target wavelengths, target intensities, a target temporal distribution, and/or a target spatial distribution. The target attribute(s) of the ultraviolet radiation can correspond to at least one of a plurality of selectable operating configurations including a storage life preservation operating configuration, a disinfection operating configuration, an ethylene decomposition operating configuration, and/or the like.

Abstract: An apparatus for sanitizing a stethoscope head. The apparatus includes a housing, a reservoir disposed within the housing for containing the sanitizing fluid, one or more applicator pads mounted on the housing, and a dispensing valve for dispensing the sanitizing fluid from the reservoir onto the applicator pad.

Abstract: The present invention relates to a sterilizer using a hydrogen peroxide solution as a disinfectant, which includes: a disinfectant lifting and lowering unit capable of housing and transporting a disinfectant container filled with disinfectant; a sting unit which opens the disinfectant container; and a drain unit which drains discharging disinfectant from the disinfectant container, wherein the disinfectant lifting and lowering unit and the stinger unit are lifted and lowered along a transport guide provided in the housing. Since it is possible to supply hydrogen peroxide to the sterilizer without frequent replacement of the hydrogen peroxide container as disinfectant many times, there is an effect that sterilization of the sterilizer can be quickly performed.

Abstract: A solution for disinfecting electronic devices is provided. An ultraviolet radiation source is embedded within an ultraviolet absorbent case. While the electronic device is within the ultraviolet absorbent case, ultraviolent radiation is directed at the electronic device. A monitoring and control system monitors a plurality of attributes for the electronic device, which can include: a frequency of usage for the device, a biological activity at a surface of the device, and a disinfection schedule history for the device. Furthermore, the monitoring and control system can detect whether the device is being used. Based on the monitoring, the monitoring and control system controls the ultraviolet radiation directed at the electronic device.

Abstract: Disclosed herein are various embodiments of sterilization tray dividers and related devices, systems and methods. In one embodiment, a sterilization tray divider comprises a divider wall comprising a flexible material able to withstand medical sterilization processes and chemicals.

Abstract: The present invention relates to the field of perfumery. It relates more particularly to perfume dispensing device. The device of the present invention comprises dispensing means and a liquid composition including a perfume and selected compounds which impacts the fragrance perception diffused in the surrounding air during use.

Abstract: An apparatus for treating air includes a housing with an air inlet and an air outlet, the housing enclosing an air treatment zone and an ozone removal zone, wherein the ozone removal zone is positioned downstream of the air treatment zone with respect to a flow direction of the air being treated, an ozone generator in the air treatment zone configured to generate ozone from the air, wherein the ozone generated by the ozone generator treats the air in the air treatment zone, catalyst in the ozone removal zone that removes at least a portion of the ozone generated the ozone generator, a particle matter (PM) filter positioned between the air treatment zone and the ozone removal zone, wherein the ozone generated by the ozone generator treats the PM filter, and an air mover positioned near the air outlet configured to draw the air through the air inlet.

Abstract: The present disclosure provides compositions comprising at least one eugenol-containing odor neutralizing agent and at least one film forming agent for treating, reducing or neutralizing malodors.

Abstract: A modular, integrated, combination air purification and aroma diffuser includes a UV and catalytic oxidation germicidal cell and multiple filtrations as pre-treatment of air diffusing essential oils or other liquids as ultra-fine droplets entrained in airflow into enclosed, habitable spaces. Liquid microbicide, insecticide, fumigant, or aroma therapy is kept cleaner by eradication of microbes. Comparatively larger droplets are separated out and recycled to the reservoir after initial atomization. An electrical module, between a purifier and filters upstream and a diffuser downstream, includes a pump, a fan, and a controller for both. Staged, double-eduction, triple-separation processes include a micro-cyclone for quiet, well diffused flow of ultra-fine droplets.

Abstract: An apparatus for treating air includes a housing with an air inlet and an air outlet, the housing enclosing an air treatment zone and an ozone removal zone, wherein the ozone removal zone is positioned downstream of the air treatment zone with respect to a flow direction of the air being treated, an ozone generator in the air treatment zone configured to generate ozone from the air, wherein the ozone generated by the ozone generator treats the air in the air treatment zone, catalyst in the ozone removal zone that removes at least a portion of the ozone generated the ozone generator, a particle matter (PM) filter positioned between the air treatment zone and the ozone removal zone, wherein the ozone generated by the ozone generator treats the PM filter, and an air mover positioned near the air outlet configured to draw the air through the air inlet.

Abstract: A germicidal facemask apparatus and related method, comprising: an inner facemask shell comprising at least one inner shell vent thereof; an outer facemask shell shaped to substantially conform to the inner facemask shell; a substantially-airtight attachment of the outer shell with the inner shell about perimeters thereof; a substantially airtight and light-reflective air cavity between the inner and outer facemask shells, formed by the substantially airtight attachment of the outer shell with the inner shell about the perimeters, and by inner shell and outer shell substantially-reflective materials; and an ultraviolet light source configured to introduce ultraviolet light into the air cavity between the inner and outer facemask shells and for the ultraviolet light to substantially permeate the air cavity by virtue of the substantially-reflective materials on the front surface of the inner facemask shell and on the rear surface of the outer facemask shell.

Abstract: The present invention relates to a photocatalytic apparatus and a heating, ventilating, and air conditioning (HVAC) equipment for a vehicle comprising the same and, more specifically, to a photocatalytic apparatus and HVAC equipment for a vehicle comprising the same, wherein the photocatalytic apparatus may sterilize and deodorize an evaporator in addition to purifying air introduced into an HVAC case and may continuously maintain sterilization and deodorization functions by efficiently radiating heat generated from the photocatalytic apparatus.

Abstract: Multilayer thermoplastic films, and laminates and articles comprising the films, wherein the film comprises at least one inner layer and at least two outer layers, wherein the inner layer comprises a polymeric composition comprising from about 55% to about 95% of one or more non-hydrogenated styrenic block copolymers, olefinic block copolymers, or combinations thereo; and each outer layer comprises at least 20% polypropylene and has a thickness of from about 5% to about 15% of the total film thickness, and further wherein the film has a constant force tear propagation of about 20% or less.

Abstract: The present invention relates to skin dressings that are useful in the treatment of conditions associated with tissue ischaemia and skin lesions including those that are infected, such as burns and surgical wounds and chronic wounds such as but not limited5 to diabetic foot ulcers and venous leg ulcers. The skin dressings are also useful to effect transdermal delivery of pharmaceutically active agents.

Abstract: Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.

Abstract: Provided are an alloy member which is usable in organisms, makes use of features of bio-affinity and biodegradability of magnesium, and is able to realize required duration of biodegradability, and a production method therefor. According to the present invention, the alloy member usable in organisms includes a base body that contains a magnesium alloy, a first protective layer that contains an oxide derived from a component of the base body or a complex of an oxide and a hydroxide derived from a component of the base body, and a second protective layer that contains a hydroxide derived from a component of the base body.

Abstract: A calcium phosphate apatite cement-forming composition comprises an apatite-forming calcium-based precursor powder and from 1 to 30 wt %, based on the weight of the precursor powder, of dicalcium pyrophosphate powder or or sodium pyrophosphate powder. Apatite cements formed form such compositions may be used in implants for correcting bone defects. Methods for bone defect repair employ implants formed from such apatite cements and slow implant resorption and/or improve in vivo bone induction in a patient.